%20Ver-2.png)
In vivo CAR-Monocytes will treat the 90% of cancers globally that are solid tumors.
CAR-Monocytes address the challenges of CAR-T for Solid Tumors
Our immune system can destroy cancer cells
CAR-T works in blood cancers but fails in solid tumors because it activates cells that can’t reach or persist in solid tumors. It also relies on complex, patient-specific manufacturing, which results in high costs and difficulties scaling to larger populations.
Our approach is different
We deliver mRNA directly into monocyte progenitors inside the bone marrow, instructing them to generate tumor-killing macrophages in vivo. It’s faster, scalable, and cost-effective.
Bone marrow-targeted delivery vehicles are the key to enabling in vivo CAR-M
> 1,000,000 Novel lipids designed with Al
> 300 Lipid Nanoparticles tested in non-human primates
>10x improvements in bone marrow bio-accumulation in NHP
> 20x improvements in expression in rodents
